Vericiguat comment watch save

  • TRADE NAME: Verquvo (Merck Sharpe & Dohme)
  • INDICATIONS:

    To reduce risk of cardiovascular death and hospitalization for heart failure in chronic heart failure


  • CLASS: Guanylate cyclase stimulator
  • HALF-LIFE: 30 hours (in patients with heart failure)
  • FDA APPROVAL DATE: 01/19/2021
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    PDE-5 inhibitors, Sildenafil

EMBRYO-FETAL TOXICITY: DO NOT ADMINISTER VERICIGUAT TO A PREGNANT FEMALE BECAUSE IT MAY CAUSE FETAL HARM.

FEMALES OF REPRODUCTIVE POTENTIAL: EXCLUDE PREGNANCY BEFORE THE START OF TREATMENT. TO PREVENT PREGNANCY, FEMALES OF REPRODUCTIVE POTENTIAL MUST USE EFFECTIVE FORMS OF CONTRACEPTION DURING TREATMENT AND FOR ONE MONTH AFTER STOPPING TREATMENT.

See full prescribing information for complete boxed warning

Please login to view the rest of this drug profile.

Page last updated 12/08/2024

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top